Filing Details

Accession Number:
0001399529-21-000120
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-17 21:18:54
Reporting Period:
2021-06-15
Accepted Time:
2021-06-17 21:18:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA Pharmaceutical Preparations (2834) 205993609
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1813985 M. Regina Paglia C/O Dicerna Pharmaceuticals, Inc.
75 Hayden Avenue
Lexington MA 02421
Chief Human Resources Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-15 381 $0.00 381 No 4 M Direct
Common Stock Disposition 2021-06-15 112 $35.74 269 No 4 F Direct
Common Stock Acquisiton 2021-06-16 20,000 $12.93 20,269 No 4 M Direct
Common Stock Acquisiton 2021-06-16 10,000 $22.58 30,269 No 4 M Direct
Common Stock Acquisiton 2021-06-16 1,564 $26.62 31,833 No 4 M Direct
Common Stock Disposition 2021-06-16 31,464 $35.63 369 No 4 S Direct
Common Stock Disposition 2021-06-16 100 $36.15 269 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2021-06-15 381 $0.00 381 $0.00
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-06-16 20,000 $0.00 20,000 $12.93
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-06-16 10,000 $0.00 10,000 $22.58
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-06-16 1,564 $0.00 1,564 $26.62
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,144 No 4 M Direct
103,414 2029-02-28 No 4 M Direct
52,500 2030-01-07 No 4 M Direct
5,261 2030-06-30 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
  2. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
  3. The Reporting Person sold an aggregate of 31,564 shares of Common Stock on June 16, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 11.35% of 278,052 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
  4. Represents RSUs that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer on each applicable vesting date.
  5. The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.
  6. The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2020, and the remaining vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.
  7. The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of July 2020, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.